Search research articles
Contact Us
Filters
Showing results (881-890 of 955) with videos related to
Page
of 96
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2022
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)
Seema A Khan, Fengmin Zhao, Lori J Goldstein, et al.
Journal of Clinical Medicine
|
July 27, 2024
Implementation of a Co-Design Strategy to Develop a Dashboard to Support Shared Decision Making in Advanced Cancer and Chronic Kidney Disease
Victoria Morken, Laura M Perry, Ava Coughlin, et al.
The Oncologist
|
December 15, 2025
Intergroup Randomized Phase III Study of Adjuvant FOLFIRI, FOLFOX, or 5-FU/Leucovorin for Stage II/III Rectal Cancer: ECOG-ACRIN E3201
Audrey E Kam, Fengmin Zhao, Neal J Meropol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
Leonard J Appleman, Se Eun Kim, Wayne B Harris, et al.
Lancet (London, England)
|
November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I Rini, Bernard Escudier, Piotr Tomczak, et al.
Plos One
|
September 4, 2020
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
John Devin Peipert, Austin G Kulasekararaj, Anna Gaya, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
May 1, 2024
Efficient measurement of multiple ventricular assist device patient-reported outcomes: Creation of a 20-item profile from the MCS A-QOL study
Kathleen L Grady, Michael A Kallen, David Cella, et al.
Journal of the American Medical Informatics Association : JAMIA
|
August 2, 2024
Shared decision-making and disease management in advanced cancer and chronic kidney disease using patient-reported outcome dashboards
David Cella, Maja Kuharic, John Devin Peipert, et al.
Journal of the National Cancer Institute
|
October 21, 2022
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials
Michael E Roth, Susan K Parsons, Patricia A Ganz, et al.
Blood Advances
|
August 21, 2024
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia
Betty K Hamilton, Bhavik J Pandya, Cristina Ivanescu, et al.
Page
of 96
Search research articles
Search
Showing results (881-890 of 955) with videos related to
Sort By:
Page
of 96
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2022
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)
Seema A Khan, Fengmin Zhao, Lori J Goldstein, et al.
Journal of Clinical Medicine
|
July 27, 2024
Implementation of a Co-Design Strategy to Develop a Dashboard to Support Shared Decision Making in Advanced Cancer and Chronic Kidney Disease
Victoria Morken, Laura M Perry, Ava Coughlin, et al.
The Oncologist
|
December 15, 2025
Intergroup Randomized Phase III Study of Adjuvant FOLFIRI, FOLFOX, or 5-FU/Leucovorin for Stage II/III Rectal Cancer: ECOG-ACRIN E3201
Audrey E Kam, Fengmin Zhao, Neal J Meropol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
Leonard J Appleman, Se Eun Kim, Wayne B Harris, et al.
Lancet (London, England)
|
November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I Rini, Bernard Escudier, Piotr Tomczak, et al.
Plos One
|
September 4, 2020
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
John Devin Peipert, Austin G Kulasekararaj, Anna Gaya, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
May 1, 2024
Efficient measurement of multiple ventricular assist device patient-reported outcomes: Creation of a 20-item profile from the MCS A-QOL study
Kathleen L Grady, Michael A Kallen, David Cella, et al.
Journal of the American Medical Informatics Association : JAMIA
|
August 2, 2024
Shared decision-making and disease management in advanced cancer and chronic kidney disease using patient-reported outcome dashboards
David Cella, Maja Kuharic, John Devin Peipert, et al.
Journal of the National Cancer Institute
|
October 21, 2022
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials
Michael E Roth, Susan K Parsons, Patricia A Ganz, et al.
Blood Advances
|
August 21, 2024
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia
Betty K Hamilton, Bhavik J Pandya, Cristina Ivanescu, et al.
Page
of 96